BR112022023154A2 - Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição - Google Patents

Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição

Info

Publication number
BR112022023154A2
BR112022023154A2 BR112022023154A BR112022023154A BR112022023154A2 BR 112022023154 A2 BR112022023154 A2 BR 112022023154A2 BR 112022023154 A BR112022023154 A BR 112022023154A BR 112022023154 A BR112022023154 A BR 112022023154A BR 112022023154 A2 BR112022023154 A2 BR 112022023154A2
Authority
BR
Brazil
Prior art keywords
compounds
preparing
tumor tissue
marking
composition
Prior art date
Application number
BR112022023154A
Other languages
English (en)
Portuguese (pt)
Inventor
Tran-Guyon Joanne
Guyon Vincent
Scherninski François
Original Assignee
Proimaging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proimaging filed Critical Proimaging
Publication of BR112022023154A2 publication Critical patent/BR112022023154A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112022023154A 2020-05-15 2021-05-12 Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição BR112022023154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2004868A FR3110165B1 (fr) 2020-05-15 2020-05-15 Nouveaux composés fluorescents pour le marquage de tissu tumoral
PCT/FR2021/050832 WO2021229188A1 (fr) 2020-05-15 2021-05-12 Nouveaux composés fluorescents pour le marquage de tissu tumoral

Publications (1)

Publication Number Publication Date
BR112022023154A2 true BR112022023154A2 (pt) 2023-02-07

Family

ID=72644317

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023154A BR112022023154A2 (pt) 2020-05-15 2021-05-12 Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição

Country Status (9)

Country Link
US (1) US20230203014A1 (https=)
EP (1) EP4149925A1 (https=)
JP (2) JP2023525601A (https=)
KR (1) KR20230010713A (https=)
CN (2) CN115605459A (https=)
BR (1) BR112022023154A2 (https=)
CA (1) CA3178232A1 (https=)
FR (1) FR3110165B1 (https=)
WO (1) WO2021229188A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150222A1 (en) * 2022-02-02 2023-08-10 Vergent Bioscience, Inc. Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment
CN114751907A (zh) * 2022-03-17 2022-07-15 南京诺源医疗器械有限公司 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途
CN116947829B (zh) * 2023-07-05 2025-09-23 上海内瑟汐医疗科技有限公司 一种基于新吲哚菁绿ir820的荧光化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06145539A (ja) * 1992-11-04 1994-05-24 Fuji Photo Film Co Ltd シアニン化合物
JPH07287346A (ja) * 1994-04-08 1995-10-31 E I Du Pont De Nemours & Co 近赤外ハレーション防止用の新規なエーテル色素を有する写真エレメント
GB2337523A (en) * 1998-04-29 1999-11-24 Nycomed Imaging As Light imaging contrast agents
JP2005220045A (ja) * 2004-02-04 2005-08-18 Konica Minolta Medical & Graphic Inc 蛍光造影剤
CN102268191B (zh) * 2010-06-06 2013-08-14 史春梦 七甲川吲哚花菁染料及其合成方法和应用
CN103911017B (zh) * 2012-12-28 2017-09-15 浙江海正药业股份有限公司 菁染料化合物及其制备方法、用于光动力学疗法的双重功能剂及其制备方法
CN105693590B (zh) * 2016-01-15 2019-01-15 复旦大学 一种pH控制识别肿瘤细胞的光热试剂及其制备方法和应用
KR101980292B1 (ko) * 2017-08-03 2019-05-20 (주)바이오액츠 형광 화합물 및 이의 제조방법
EP3517146A1 (en) * 2018-01-26 2019-07-31 Université de Strasbourg Fluorescent polymeric coating film for medical devices

Also Published As

Publication number Publication date
FR3110165A1 (fr) 2021-11-19
US20230203014A1 (en) 2023-06-29
JP2023525601A (ja) 2023-06-16
JP2026042845A (ja) 2026-03-11
FR3110165B1 (fr) 2022-10-28
CA3178232A1 (fr) 2021-11-18
WO2021229188A1 (fr) 2021-11-18
EP4149925A1 (fr) 2023-03-22
CN115605459A (zh) 2023-01-13
KR20230010713A (ko) 2023-01-19
CN121471129A (zh) 2026-02-06

Similar Documents

Publication Publication Date Title
BR112022023154A2 (pt) Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição
BR112021024810A2 (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BR112018003822A2 (pt) material auxiliar para promover crescimento de tecido em um cólon
PL406033A1 (pl) Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
CO2022000481A2 (es) Inhibidores de enzimas
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
WO2020023911A3 (en) Near-infrared nerve-sparing fluorophores
BR112022009086A2 (pt) Inibidores alostéricos de egfr e métodos de uso dos mesmos
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BR102016007036A8 (pt) material de reparo de tecido derivado de pele de peixe e método de fabricação do mesmo
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
BR112016014601A2 (pt) Composição dermatológica, dispositivo aplicador e método para preparar uma composição dermatológica
BR112022014580A2 (pt) Compostos fluoróforos à base de oxazina para imageamento nervo-específico
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
BR112015031984A2 (pt) gel biocompatível compreendendo nanopartículas e/ou agregados de nanopartículas; e kit compreendendo um gel biocompatível

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]